| scholarly article | Q13442814 |
| P50 | author | Surasak Saokaew | Q83145170 |
| David D Stenehjem | Q85904414 | ||
| P2093 | author name string | Kuan-Ling Kuo | |
| P2860 | cites work | Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management | Q28273281 |
| Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). | Q32147934 | ||
| Breakthrough pain: definition, prevalence and characteristics | Q33435886 | ||
| Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. | Q34251507 | ||
| Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms | Q36057778 | ||
| Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer | Q36058479 | ||
| Drug utilization review on a tertiary palliative care unit | Q36485402 | ||
| The treatment of breakthrough pain | Q36728954 | ||
| The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. | Q37245357 | ||
| Assessment and classification of cancer breakthrough pain: a systematic literature review | Q37710813 | ||
| Comparison of continuous subcutaneous and intravenous hydromorphone infusions for management of cancer pain | Q39234596 | ||
| Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. | Q39256721 | ||
| A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial | Q39297854 | ||
| A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer | Q39344435 | ||
| Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients | Q39449130 | ||
| Description and predictors of direct and indirect costs of pain reported by cancer patients | Q40607097 | ||
| An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain | Q40797392 | ||
| Cost issues related to pain management: report from the Cancer Pain Panel of the Agency for Health Care Policy and Research | Q41034280 | ||
| Cancer pain management: newer perspectives on opioids and episodic pain | Q41703866 | ||
| Distribution of emergency department costs | Q42057897 | ||
| Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension tr | Q43288823 | ||
| Morphine remains gold standard in breakthrough cancer pain | Q46183060 | ||
| An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer | Q48279154 | ||
| The Zero Acceptance of Pain (ZAP) Quality Improvement Project: evaluation of pain severity, pain interference, global quality of life, and pain-related costs. | Q52282279 | ||
| Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. | Q53288431 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 167-175 | |
| P577 | publication date | 2013-05-20 | |
| P1433 | published in | Journal of Pain and Palliative Care Pharmacotherapy | Q6295706 |
| P1476 | title | The pharmacoeconomics of breakthrough cancer pain | |
| P478 | volume | 27 |
| Q33440717 | A smartphone-based pain management app for adolescents with cancer: establishing system requirements and a pain care algorithm based on literature review, interviews, and consensus |
| Q38211002 | Breakthrough pain in elderly patients with cancer: treatment options |
| Q39181601 | Comparing the effectiveness of intranasal fentanyl spray with oral transmucosal fentanyl citrate in breakthrough pain |
| Q47888494 | Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain |
| Q39214375 | Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain |
| Q39197889 | Fentanyl Formulations in the Management of Pain: An Update |
| Q49500997 | Martial arts intervention decreases pain scores in children with malignancy |
| Q89425464 | Observational Study Evaluating the Economic Impact of Breakthrough Pain in Cancer Patients in Clinical Practice in Spain: The IMDI Study |
| Q90407549 | Pain Squad+ smartphone app to support real-time pain treatment for adolescents with cancer: protocol for a randomised controlled trial |
| Q52601777 | Perceptions of Adolescents With Cancer Related to a Pain Management App and Its Evaluation: Qualitative Study Nested Within a Multicenter Pilot Feasibility Study. |
| Q34690059 | Pharmacologic management of adult breakthrough cancer pain. |
| Q91496796 | Prevalence and characterization of breakthrough pain in patients with cancer in Spain: the CARPE-DIO study |
| Q42535068 | Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion |
| Q57286683 | The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study |
| Q38586530 | Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care |
| Q39179543 | Ultrasound-Guided Radiofrequency Treatment of Intercostal Nerves for the Prevention of Incidental Pain Arising Due to Rib Metastasis |
| Q47716433 | Use of oral formulations of fentanyl for breakthrough cancer pain |
| Q36197349 | Utilising out-of-hours primary care for assistance with cancer pain: a semi-structured interview study of patient and caregiver experiences |
| Q55077608 | Prise en charge pharmacologique de la douleur cancéreuse paroxystique chez l’adulte. |
Search more.